Abstract:Introduction: We have previously demonstrated a functional impairment of NK cells in the Jak2V617F murine model and peripheral blood cells from patients with Myeloproliferative Neoplasms, with emphasis on the increased frequency of immature NK cells and reduced cytotoxicity of the more mature CD27-CD11b+ fraction. It is not known whether MPN initiating cells are intrinsically resistant to tumor immunity or whether they can modify NK cells of the leukemic microenvironment, leading to dysfunction. Aims: To clarify these mechanisms, the present work aimed to model the leukemic exposure of normal NK cells and verify their modifications using a Jak2V617F chimeric transplant model. Methods: For transplantation, a non-myeloablative conditioning (single sublethal irradiation of 400cGy) was performed to partially preserve the recipient's hematopoiesis (50-60% of donor engraftment). 5 x 10 6 total bone marrow (BM) cells from Jak2VF or Jak2WT control animals (both C57BL/6, CD45.2) were injected retro-orbitally into wild-type mice (C57BL/6, CD45.1, N=6 per group). Engraftment was evaluated by flow cytometry according to CD45.2/CD45.1 differential ratio. After engraftment was confirmed, frequency, receptors, and functional subtypes of exposed NK cells were evaluated. NK cytotoxicity against YAC-1 target cells was evaluated after culture with serum and supernatant of whole BM from chimeric animals. Results: The frequency of host NK cells (CD45.1) exposed to Jak2VF BM was lower than that of NK cells exposed to Jak2WT BM (Jak2WT 44.05% vs Jak2VF 19.76%, p<0.0001). Evaluation of functional subtypes showed that host NK cells had a lower frequency of immature secretory (Jak2WT 44.32% vs Jak2VF 30.70%, p=0,0407) and higher frequency of tolerant (Jak2WT 12.43% vs Jak2VF 24.34%, p=0.0016) and cytotoxic (Jak2WT 7.15% vs Jak2VF 19.30%, p<0.0001) NK cells when exposed to leukemia than when exposed to normal BM. In comparison, secretory immature NK cells from the leukemic BM (CD45.2) were low numbered as compared to Jak2WT NK cells (Jak2WT 73.30% vs Jak2VF 35.74%, p<0.0001) and cytotoxic NK cells were more frequent (Jak2WT 7.28% vs Jak2VF 19.16%, p=0.0003). In addition, host NK cells presented decreased expression of the activating receptor DNAM-1 when exposed to leukemia than when exposed to normal BM (Jak2WT 51.20% vs Jak2VF 46.10%, p=0.0006), whereas CD244 and NKG2D activating receptors were not differentially expressed. In contrast, the expression of TIGIT (but not NKG2A) inhibitory receptor was increased after leukemia exposure (Jak2WT 14.83% vs 46.10%, p=0.0003). Regarding the effect of the leukemic medium on NK cells, cytotoxicity was not altered when WT NK cells were exposed to serum or BM supernatant from chimeric transplanted animals. However, NK cells exposed to Jak2VF chimeric serum were activated according to CD69 expression (Jak2WT 0.060% vs Jak2VF 0.30%, p=0.0114) but presented lower expression of the CD107a degranulation marker (Jak2WT 91.92% vs Jak2VF 62.34%, p=0.0075) than NK cells exposed to Jak2WT cells. Conclusions: Our findings demonstrated that leukemia exposure led to altered NK cell frequency and maturation distribution as demonstrated by reduced immature and an increased tolerant and cytotoxic fraction. Changes in the expression profile of activating and inhibitory receptors were also observed. Therefore, we concluded that the leukemic environment leads to NK dysfunction and that strategies that aim to control NK maturation and the interaction between stem cell ligands and functional NK receptors can be explored to restore immunosurveillance in JAK2V671F Myeloproliferative Neoplasms.

Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms

Jak2V617F Bone Marrow Exposure Leads to Dysfunction of Normal NK Cells

Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms

Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms

Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms

Natural Killer Cell Subpopulations and Inhibitory Receptor Dynamics in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms

Chronic Inflammation Deters Natural Killer Cell Fitness and Cytotoxicity in Myeloid Leukemia

NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in Multiple Myeloma

Inflammation perturbs NK cell phenotype and function in chronic myeloid leukemia (CML)

Inflamed Natural Killer cells with adhesion defects are associated with a poor prognosis in Multiple Myeloma

Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia

New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms

Frequent Activating Mutations of JAK-STAT Pathway Genes in Natural Killer Cell Lymphomas

Data from Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation <i>In Vivo</i>

Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation in Vivo

Epigenetic Scarring Leads to Irreversible NK Cell Dysfunction in Myeloid Malignancies

Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms

Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F.

JAK2V617F Megakaryocytes Promote Hematopoietic Stem/Progenitor Cell Expansion in Mice Through Thrombopoietin/MPL Signaling

Lnk Constrains Oncogenic Jak2-Induced Myeloproliferative Disease in Mice